Interventional Glaucoma

Investigators from various companies described their diagnostic offerings at the Glaucoma Research Foundation’s 2021 New Horizons Forum.

Telemedicine provides readiness in time of crisis.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.

Hisaharu Suzuki, MD, PhD, provides insight on how a handpiece maintains the anterior chamber stability even when occlusion occurs, suggesting its usefulness for a safe and efficient surgery.

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.

A new report has found that glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic.

Although minimally invasive procedure gives hope, additional research is required.

According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.

New strategies are needed to rethink how we treat glaucoma to do more than just manage eye pressure—to actually restore vision by promoting the survival of retinal ganglion cells and their axons.

There’s no shortage of diet programs—Paleo, Mediterranean, intermittent fasting—all claiming to be the best option for a healthy life. Research has shown that poor lifestyle choices, including unhealthy diets, contribute to many diseases and that simply adhering to good nutrition can even prevent some health issues.

Pressure-dependent optic nerve disease, retinal disease.

Two trials examine factors affecting the risk of disease.

MIGS drainage device offers hope for challenging cases.

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Measurements from multiple studies show benefits of rho-kinase inhibition.

Increased access is key to preventing disease progression in patients.

Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.

Visible-light optical coherence tomography proves valuable in studies.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

Physicians are left to determine which treatments can offer patients best outcomes.

Retrospective review highlights the sustained efficacy of combination procedure.

Option could prove to enhance safety for both patients and staff.

According to preliminary results, intranasally delivered ST266 is a safe treatment option.